1. A pharmaceutical composition comprising finely divided progesterone and safflower oil of type II.2. The pharmaceutical composition according to claim 1, in which the ratio of progesterone / oil is from 0.15 / 1 to 3/1, preferably from 0.25 / 1 to 2/1, preferably from 0.40 / 1 to 1/1 or more preferably 0.67 / 1.3. The pharmaceutical composition according to claim 1, wherein at least progesterone is in suspension in type II safflower oil. The pharmaceutical composition according to claim 1, comprising an estrogen or ester derivative, preferably selected from the group consisting of 17-β estradiol, estrone, 17-α ethinyl estradiol, estradiol valerate or phytoestrogens, and more preferably 17-β estradiol. The pharmaceutical composition according to claim 1, containing a suspending agent. The pharmaceutical composition of claim 5, wherein the suspending agent is Aerosil. The pharmaceutical composition according to claim 1, in the form of a soft capsule. The pharmaceutical agent of claim 1, each unit dosage form of which preferably contains from 2 mg to 600 mg of finely divided progesterone, and more preferably from 100 mg to 400 mg. Finely ground progesterone in type II safflower oil for the treatment of a physiological condition associated with insufficient secretion of progesterone. 10. The use of finely ground progesterone in safflower oil of type II for the manufacture of a medicament intended for the treatment of a physiological condition associated with insufficient secretion of progesterone. 11. The use of claim 10, wherein the drug further comprises an estrogen or derivative of an ester type, preferably selected from1. Фармацевтическая композиция, содержащая тонкоизмельченный прогестерон и сафлоровое масло типа II.2. Фармацевтическая композиция по п.1, в которой соотношение прогестерон/масло составляет от 0,15/1 до 3/1, предпочтительно от 0,25/1 до 2/1, предпочтительно от 0,40/1 до 1/1 и более предпочтительно 0,67/1.3. Фармацевтическая композиция по п.1, в кото
